Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $77
Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $77
富國銀行仍然看好ionis pharmaceuticals,將目標價下調至77美元
Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $82 to $77.
Wells Fargo 的分析師Yanan Zhu 維持ionis pharmaceuticals(納斯達克:IONS)的股票評級爲增持,將目標股價從82美元下調至77美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。